Lilly to Supply an Additional 150,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatment Options
June 29 2022 - 10:04AM
Business Wire
Bebtelovimab continues to maintain
neutralization activity against all known variants of interest and
concern
AbCellera (Nasdaq: ABCL) today announced that Eli Lilly and
Company (Lilly) has entered into a modified purchase agreement with
the U.S. government to supply an additional 150,000 doses of
bebtelovimab, the second antibody developed through AbCellera’s
collaboration with Lilly, for approximately $275 million. The
existing U.S. government supply of bebtelovimab, including the new
purchase, is expected to meet present demand through late August
2022. Delivery of doses will begin immediately and complete no
later than August 5, 2022. An option for an additional 350,000
doses to be exercised no later than September 14, 2022, will remain
in the agreement.
Details regarding Lilly's modified purchase agreement to provide
the U.S. government can be found here.
Bebtelovimab continues to maintain neutralization activity
against the most common, and fastest growing, Omicron variants
(BA.2.12.1 and BA.4/BA.5) in the United States, in addition to all
known variants of interest and concern.
About AbCellera’s Response to COVID-19
AbCellera initially mobilized its pandemic response platform
against COVID-19 in February of 2020, resulting in the discovery of
bamlanivimab, the first monoclonal antibody therapy for COVID-19 to
reach human testing and to be authorized for emergency use by the
U.S. FDA. Bamlanivimab alone and together with other antibodies has
treated at least 700,000 patients, preventing COVID-19-related
hospitalizations and death.
AbCellera’s second monoclonal antibody for COVID-19,
bebtelovimab, was developed to combat emerging variants and.
Bebtelovimab maintains binding and neutralizing activity across
currently known and reported variants of concern. Bebtelovimab has
been studied for the treatment of mild-to-moderate COVID-19 both as
a monotherapy and together with other antibodies.
AbCellera’s efforts to respond to the COVID-19 pandemic have
identified thousands of unique anti-SARS-CoV-2 human antibodies.
These include bamlanivimab, bebtelovimab, and other antibodies that
are in various stages of testing by AbCellera and its
collaborators.
Bamlanivimab and bebtelovimab were developed from antibodies
that were discovered using AbCellera’s pandemic response platform,
in partnership with the Vaccine Research Center (VRC) at the
National Institutes for Allergy and Infectious Diseases (NIAID).
AbCellera’s partner, Lilly, is responsible for development,
manufacturing, and distribution of bamlanivimab and
bebtelovimab.
AbCellera’s pandemic response capabilities were developed over
the past four years as part of the Defense Advanced Research
Projects Agency (DARPA) Pandemic Prevention Platform (P3) program.
The goal of the P3 program is to establish a robust technology
platform for pandemic response capable of developing field-ready
medical countermeasures within 60 days of isolation of an unknown
viral pathogen.
About AbCellera Biologics Inc.
AbCellera is a technology company that searches, decodes, and
analyzes natural immune systems to find antibodies that its
partners can develop into drugs to prevent and treat disease.
AbCellera partners with drug developers of all sizes, from large
pharmaceutical to small biotechnology companies, empowering them to
move quickly, reduce cost, and tackle the toughest problems in drug
development. For more information, please visit
www.abcellera.com.
AbCellera Forward-looking Statements
This press release contains forward-looking statements,
including statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. The
forward-looking statements are based on management’s current
beliefs and assumptions and on information currently available to
management. All statements contained in this release other than
statements of historical fact are forward-looking statements,
including statements regarding our ability to develop,
commercialize and achieve market acceptance of our current and
planned products and services, our research and development
efforts, and other matters regarding our business strategies, use
of capital, results of operations and financial position, and plans
and objectives for future operations.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance, or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties and
other factors are described under "Risk Factors," "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and elsewhere in the documents we file with the
Securities and Exchange Commission from time to time. We caution
you that forward-looking statements are based on a combination of
facts and factors currently known by us and our projections of the
future, about which we cannot be certain. As a result, the
forward-looking statements may not prove to be accurate. The
forward-looking statements in this press release represent our
views as of the date hereof. We undertake no obligation to update
any forward-looking statements for any reason, except as required
by law.
Source: AbCellera Biologics Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220629005715/en/
Media: Jessica Yingling, Ph.D.; media@abcellera.com,
+1(236)521-6774 Business Development: Neil Berkley;
bd@abcellera.com, +1(604)559-9005 Investor Relations:
Melanie Solomon; ir@abcellera.com, +1(778)729-9116
AbCellera Biologics (NASDAQ:ABCL)
Historical Stock Chart
From Apr 2024 to May 2024
AbCellera Biologics (NASDAQ:ABCL)
Historical Stock Chart
From May 2023 to May 2024